Education
About Us
Working with TipRanks
Follow Us
Oxford Biomedica (otc) (OXBDF)
:OXBDF
OXBDF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.17 - $5.95
Previous CloseN/A
Volume1.00K
Average Volume (3M)3.13K
Market Cap
$440.96M
Enterprise Value$345.76M
Total Cash (Recent Filing)£103.72M
Total Debt (Recent Filing)£111.46M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Apr 09, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding105,974,850
10 Day Avg. Volume2,083
30 Day Avg. Volume3,133
Standard Deviation0.16
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.94
Price to Cash Flow (P/CF)-32.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.30Price Target Upside47.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Oxford BioMedica News
PremiumCompany Announcements
Oxford Biomedica Announces Total Voting Rights
PremiumCompany Announcements
Oxford Biomedica to Present at Global Healthcare Conference
PremiumCompany Announcements
M&G Plc Increases Stake in Oxford BioMedica
PremiumCompany Announcements
Oxford BioMedica Announces Change in Major Holdings
---
Bulls Say, Bears Say
Bulls Say
EarningsStrong growth is expected with revenues projected to increase by 42%-44%, aligning with previous guidance.
Market PositionOXB is seen as a unique and undervalued asset in the UK-listed life science space well positioned to capture a meaningful proportion of the outsourced viral vector supply market in the fast-growing cell and gene therapy space.
Bears Say
Macroeconomic EnvironmentThere is some level of caution on the outlook due to macroeconomic headwinds and the continued tight funding environment.
---
Options Prices
Currently, No data available
---
Ownership Overview
<0.01% Insiders
0.26% Mutual Funds
2.15% Other Institutional Investors
97.49% Public Companies and
Individual Investors
OXBDF FAQ
What was Oxford Biomedica (otc)’s price range in the past 12 months?
Oxford Biomedica (otc) lowest stock price was $2.17 and its highest was $5.95 in the past 12 months.
What is Oxford Biomedica (otc)’s market cap?
Oxford Biomedica (otc)’s market cap is $440.96M.
When is Oxford Biomedica (otc)’s upcoming earnings report date?
Oxford Biomedica (otc)’s upcoming earnings report date is Apr 09, 2025 which is in 36 days.
How were Oxford Biomedica (otc)’s earnings last quarter?
Oxford Biomedica (otc) released its earnings results on Sep 23, 2024. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.356 by -$0.034.
Is Oxford Biomedica (otc) overvalued?
According to Wall Street analysts Oxford Biomedica (otc)’s price is currently Undervalued.
Does Oxford Biomedica (otc) pay dividends?
Oxford Biomedica (otc) does not currently pay dividends.
What is Oxford Biomedica (otc)’s EPS estimate?
Oxford Biomedica (otc)’s EPS estimate is -0.09.
How many shares outstanding does Oxford Biomedica (otc) have?
Oxford Biomedica (otc) has 105,974,850 shares outstanding.
What happened to Oxford Biomedica (otc)’s price movement after its last earnings report?
Oxford Biomedica (otc) reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.356. Following the earnings report the stock price went down -1.639%.
Which hedge fund is a major shareholder of Oxford Biomedica (otc)?
Currently, no hedge funds are holding shares in OXBDF
---
Oxford BioMedica Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.30 (47.20% Upside)
$6.30 (47.20% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
95.88%
12-Months-Change
Fundamentals
Return on Equity
-117.88%
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
Oxford Biomedica (otc)
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the Platform and Product segment. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1996 and is headquartered in Oxford, the United Kingdom.
---
OXBDF Stock 12 Month Forecast
Average Price Target
$6.30
▲(47.20% Upside)
Technical Analysis
Futura Medical
―
HUTCHMED (China) Limited
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
Best Analysts Covering OXBDF
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-4.25%
reiterated a buy rating 3 months ago
Copying Charles Weston's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -4.25% per trade.
---